Skip to main content
Clinical Trials/NL-OMON37801
NL-OMON37801
Completed
Phase 4

Cross-sectional study of 24-hours blood pressure measures and left ventricular mass using echocardiograms in late adolescents and adults with ADHD. - ADDUCE: blood pressure and left ventrikel mass in ADHD.

niversitair Medisch Centrum Sint Radboud0 sites320 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Bloeddruk
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
320
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • Target group:
  • Patients with ADHD according to DSM\-IV criteria (any subtype), based on clinical diagnosis, and confirmed by a structured interview \[depending on local procedures: ADHD module of the K\-SADS (Kaufman et al., 2000\) or CAADID (Conners Adult ADHD Diagnostic Interview for DSM\-IV) (www.mhs.com/) or DIVA (Diagnostic Interview for Adult ADHD) (www.divacenter.eu/Content/Downloads/DIVA\_2\.pdf).
  • Aged between 15 and 25 years.
  • Any comorbidity is allowed.
  • Any comedication is allowed.
  • Treated with methylphenidate (IR or ER preparations) for 3 years or longer, continuously.;Note: we will attempt to recruit at least 50% of the participants of the target group being treated continuously for 3 years with a minimum effective dose of 0\.5 mg methylphenidate /kg/day). Being treated continuously means being prescribed methylphenidate continuously but may include the presence of drug holidays. We will measure adherence by asking questions about drug holidays and % of the overall dose taken. We will allow for some variation in dosages prescribed to be able to analyze dose\-response relationships.;Control group:
  • Patients with ADHD according to DSM\*IV criteria (any subtype), based on clinical diagnosis.
  • Aged between 15 and 25 years.
  • Any comorbidity is allowed.
  • Any comedication is allowed.

Exclusion Criteria

  • All Groups: Treatment with dexamfetamine or atomoxetine.
  • ADHD controls: Treatment with methylphenidate.

Outcomes

Primary Outcomes

Not specified

Similar Trials